108 related articles for article (PubMed ID: 6092551)
1. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Mitchell JB; Russo A; Aiken M; Morstyn G; Hsu SM; Rowland J; Glatstein E
J Clin Oncol; 1984 Oct; 2(10):1144-50. PubMed ID: 6092551
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.
Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P
Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization of hematopoietic precursor cells (CFUc) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR).
Mitchell JB; Kinsella TJ; Russo A; McPherson S; Rowland J; Smith BH; Kornblith PL; Glatstein E
Int J Radiat Oncol Biol Phys; 1983 Apr; 9(4):457-63. PubMed ID: 6303991
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors.
Matsutani M; Kohno T; Nagashima T; Nagayama I; Matsuda T; Hoshino T; Sano K
Radiat Med; 1988; 6(1):33-9. PubMed ID: 3045898
[TBL] [Abstract][Full Text] [Related]
5. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a phase I and drug incorporation study.
Eisbruch A; Robertson JM; Johnston CM; Tworek J; Reynolds KR; Roberts JA; Lawrence TS
J Clin Oncol; 1999 Jan; 17(1):31-40. PubMed ID: 10458215
[TBL] [Abstract][Full Text] [Related]
6. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.
Hegarty TJ; Thornton AF; Diaz RF; Chandler WF; Ensminger WD; Junck L; Page MA; Gebarski SS; Hood TW; Stetson PL
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):421-8. PubMed ID: 2168357
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
[TBL] [Abstract][Full Text] [Related]
8. Identification of bromodeoxyuridine in malignant and normal cells following therapy: relationship to complications.
Morstyn G; Kinsella T; Hsu SM; Russo A; Gratzner H; Mitchell J
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1441-5. PubMed ID: 6469767
[TBL] [Abstract][Full Text] [Related]
9. In vivo incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells.
Morstyn G; Kinsella T; Shan CS; Whang-Peng J; Russo A; Mitchell JB
Exp Hematol; 1985 May; 13(4):289-94. PubMed ID: 3987831
[TBL] [Abstract][Full Text] [Related]
10. Intra-arterial 5-bromo-2-deoxyuridine (BUdR) radiosensitization with external beam radiation in rhesus monkeys: toxicity study.
Greenberg HS; Chandler WF; Diaz RF; Averill DR; Gebarski SS; Lichter AS; Ensminger WD
J Neurooncol; 1988 Dec; 6(4):349-54. PubMed ID: 3221261
[TBL] [Abstract][Full Text] [Related]
11. Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody.
Morstyn G; Hsu SM; Kinsella T; Gratzner H; Russo A; Mitchell JB
J Clin Invest; 1983 Nov; 72(5):1844-50. PubMed ID: 6355188
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization with carotid intra-arterial bromodeoxyuridine +/- 5-fluorouracil biomodulation for malignant gliomas.
Greenberg HS; Chandler WF; Ensminger WD; Sandler H; Junck L; Page MA; Crane D; McKeever P; Tankanow R; Bromberg J
Neurology; 1994 Sep; 44(9):1715-20. PubMed ID: 7936303
[TBL] [Abstract][Full Text] [Related]
13. Combined radiosensitizer infusion and irradiation of osteogenic sarcomas.
Goffinet DR; Kaplan HS; Donaldson SS; Bagshaw MA; Wilbur JR
Radiology; 1975 Oct; 117(1):211-4. PubMed ID: 1080572
[TBL] [Abstract][Full Text] [Related]
14. [An experimental study on radiotherapy for esophageal cancer using intraluminal administration of radiosensitizer].
Ikuta H; Hamabe Y; Saitoh Y
Nihon Geka Gakkai Zasshi; 1994 Sep; 95(9):636-42. PubMed ID: 7838104
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme.
Kinsella TJ; Collins J; Rowland J; Klecker R; Wright D; Katz D; Steinberg SM; Glastein E
J Clin Oncol; 1988 May; 6(5):871-9. PubMed ID: 2835444
[TBL] [Abstract][Full Text] [Related]
16. The clinical rationale for S-phase radiosensitization in human tumors.
McGinn CJ; Kinsella TJ
Curr Probl Cancer; 1993; 17(5):273-321. PubMed ID: 8281809
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors.
Phuphanich S; Levin EM; Levin VA
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1769-72. PubMed ID: 6480461
[TBL] [Abstract][Full Text] [Related]
18. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas.
Greenberg HS; Chandler WF; Diaz RF; Ensminger WD; Junck L; Page MA; Gebarski SS; McKeever P; Hood TW; Stetson PL
J Neurosurg; 1988 Oct; 69(4):500-5. PubMed ID: 3047341
[TBL] [Abstract][Full Text] [Related]
19. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
20. Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation.
McLaughlin PW; Lawrence TS; Seabury H; Nguyen N; Stetson PL; Greenberg HS; Mancini WR
Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):601-7. PubMed ID: 7928491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
